Can I screen against whole cells using your phage-displayed peptide libraries?

Yes, we offer "Cell-Panning" services. This is particularly useful for discovering ligands for cell-surface receptors in their native environment without the need for protein purification.

What library diversity do you offer?

Our premade peptide libraries typically feature a diversity of 10^9 to 10^11 unique transformants, providing a vast sequence space for identifying high-affinity binders.

Is Repertoire Analysis necessary for every project?

While not mandatory, it is highly recommended. Traditional Sanger sequencing only looks at 50–100 clones, which is a tiny fraction of the enriched pool. Repertoire Analysis via NGS examines millions of sequences, significantly increasing the probability of finding the best lead.

How do you handle target-unrelated peptides (TUPs)?

We use bioinformatic filters and "subtractive panning" strategies (pre-clearing the library against non-target surfaces) to eliminate peptides that bind to the plastic, the phage itself, or common contaminants.

Can you discover peptides that cross the Blood-Brain Barrier (BBB)?

Yes, we utilize in vivo panning and specialized in vitro BBB models to identify bioactive peptides with transcytosis properties.

What is the minimum amount of target protein required?

Typically, 1–5 mg of high-purity protein is sufficient for a full discovery campaign. However, this can vary based on the target type and screening strategy.

Do you provide the genetic sequence of the discovered peptides?

Absolutely. We provide the full amino acid sequence, the corresponding DNA sequence from the phage clone, and a comprehensive report of the Repertoire Analysis.

Can discovered peptides be used directly for clinical diagnosis?

Our services are currently for research use only (RUO). While the leads we discover can be developed into clinical candidates, the discovery phase itself is not intended for direct clinical diagnosis.

What makes Creative Biolabs a leader in the development of peptide ligands?

Our dual expertise in molecular biology (phage display) and high-end bioinformatics, combined with two decades of experience across thousands of successful projects, makes us a premier partner in the biotech industry.

Advanced Bioactive Peptide Discovery Service

Background Platform Workflow Application Advantage Related Service FAQ Online Inquiry

In the rapidly evolving landscape of biotherapeutics and molecular diagnostics, Bioactive Peptides have emerged as pivotal players. These short chains of amino acids act as highly specific Peptide Ligands, modulating biological processes with surgical precision. At Creative Biolabs, with over 20 years of industry-leading expertise, we offer a comprehensive Bioactive Peptide Discovery Service designed to accelerate your research from initial screening to lead optimization. Our approach integrates world-class phage-displayed peptide libraries, high-throughput screening technologies, and advanced Repertoire Analysis to identify high-affinity bioactive sequences for diverse applications.

Discuss Your Project Today

The Strategic Importance of Bioactive Peptides in Modern Biotech

Bioactive peptides are defined by their ability to exert a biological effect upon interaction with a target receptor or enzyme. Unlike small molecules, they offer superior specificity and lower toxicity; unlike large proteins, they exhibit better tissue penetration and lower manufacturing costs.

Table 1. Key Characteristics of Bioactive Peptides

Feature	Benefit to Drug Discovery
High Specificity	Minimal off-target effects and reduced side-effect profiles.
Small Molecular Weight	Enhanced ability to cross biological barriers and penetrate solid tumors.
Structural Versatility	Can be engineered into linear, cyclic, or stapled formats for stability.
Low Immunogenicity	Often derived from natural sequences, reducing the risk of immune rejection.

Our Bioactive Peptide Discovery workflow is tailored to harvest these benefits, providing clients with robust candidates for therapeutic intervention, diagnostic imaging, and biochemical research.

Our Comprehensive Platform for Bioactive Peptide Discovery

Core Technology: Phage Display and Beyond

The cornerstone of our discovery engine is the utilization of phage-displayed peptide libraries. This technology allows for the physical linkage between the peptide phenotype and its genetic genotype, enabling the screening of billions of unique sequences simultaneously.

Premade and Custom Peptide Libraries

Creative Biolabs maintains a vast collection of premade peptide libraries, including:

Linear Peptide Libraries: (e.g., 7-mer, 12-mer) for broad initial scans.
Cyclic Peptide Libraries: Constrained by disulfide bonds for enhanced metabolic stability and binding affinity.
Randomized and Targeted Libraries: Tailored to specific protein domains or motifs.

For projects requiring unique structural constraints, we specialize in the development of peptide ligands via custom library construction, ensuring the chemical space explored is perfectly aligned with your target's topography.

Fig. 1 The overview of phage display technology. (OA Literature) Fig. 1 Phage display for peptides and antibodies discovery.¹

High-Throughput Screening: The MemDX™ Platform

One of the greatest challenges in Bioactive Peptide discovery is screening against difficult targets, such as G protein-coupled receptors (GPCRs) or ion channels. To address this, Creative Biolabs utilizes the high-throughput MemDX™ platform.

The MemDX™ platform is a proprietary system designed for the efficient display and screening of peptides against membrane-associated targets in their native conformation. By stabilizing these targets in lipid environments or virus-like particles (VLPs), we ensure that the peptide ligands discovered are biologically relevant and functionally active.

Advantages of the MemDX™ Platform

Native Conformation Preservation: Screens against proteins as they exist on the cell surface.
High Signal-to-Noise Ratio: Optimized protocols to reduce non-specific binding.
Rapid Turnaround: Integrated automation allows for a high-throughput and rapid method for sequencing peptide ligands.

Advanced Repertoire Analysis for Deep Sequence Mining

Moving beyond traditional Sanger sequencing, we employ Repertoire Analysis powered by Next-Generation Sequencing (NGS). This technique provides a holistic view of the library's evolution during the biopanning process.

The Power of NGS in Peptide Discovery

By analyzing the entire sequence repertoire, we can:

Identify Rare Clones: Detect high-affinity binders that might be outcompeted in traditional plaque assays.
Monitor Enrichment Trends: Quantify how specific motifs are selected across multiple rounds of panning.
Predict SAR (Structure-Activity Relationship): Use bioinformatic tools to group sequences into clusters, identifying the essential residues for binding.

This high-throughput and rapid method for sequencing peptide ligands ensures that no potential lead is overlooked, providing a data-rich foundation for downstream optimization.

Comprehensive Workflow for Bioactive Peptide Discovery

Our integrated pipeline is designed for maximum efficiency and scientific rigor.

Step 1: Target Preparation and Validation

We work with various target formats, including recombinant proteins, whole cells, and even in vivo tissue models. Each target undergoes stringent quality control to ensure purity and functionality.
Step 2: Biopanning and Selection

Using our phage-displayed peptide libraries, we perform iterative rounds of selection. We employ diverse elution strategies (pH shift, competitive elution, or enzymatic cleavage) to isolate the most promising candidates.
Step 3: High-Throughput Sequencing and Bioinformatic Analysis

The enriched pools are subjected to NGS. Our proprietary bioinformatics suite performs Repertoire Analysis, filtering out "target-unrelated peptides" (TUPs) and identifying dominant consensus sequences.
Step 4: Peptide Synthesis and Functional Validation
Selected candidates are synthesized using solid-phase peptide synthesis (SPPS). We then conduct rigorous in vitro assays, including:
- Surface Plasmon Resonance (SPR) for affinity (KD) measurement.
- Cell-based signaling assays (e.g., cAMP, Calcium flux).
- Metabolic stability testing in serum or simulated gastric fluid.

Applications of Bioactive Peptide Ligands

The development of peptide ligands at Creative Biolabs serves a wide array of therapeutic and diagnostic sectors.

Oncology: Discovery of tumor-homing peptides that can be conjugated to cytotoxic drugs (Peptide-Drug Conjugates, PDCs) or imaging agents for precision medicine.
Antimicrobial Research: Identifying novel antimicrobial peptides (AMPs) that bypass traditional antibiotic resistance mechanisms by disrupting bacterial membranes.
Metabolic Disorders: Designing agonists or antagonists for incretin receptors (like GLP-1) to treat diabetes and obesity.
Neurobiology: Developing blood-brain barrier (BBB) penetrating peptides for the delivery of CNS therapeutics.

Why Choose Creative Biolabs?

Industry Authority: 20+ years specializing in phage display and Bioactive Peptide discovery.
Unrivaled Diversity: Our premade peptide libraries provide one of the largest sequence spaces available globally.
Target Versatility: Expertise in "hard-to-screen" membrane proteins via the high-throughput MemDX™ platform.
Data-Driven Results: Integration of sequencing peptide ligands with deep NGS repertoire mining.
Custom Stability Engineering: We don't just find sequences; we optimize them for protease resistance and metabolic half-life.

Explore Our Comprehensive Services

Creative Biolabs offers a modular suite of services tailored to address diverse research questions:

Whether you are targeting a well-characterized enzyme or a complex membrane receptor, Creative Biolabs provides the tools and expertise to turn your hypothesis into a lead candidate. Utilize our high-throughput MemDX™ platform, harness the power of Repertoire Analysis, and explore our massive premade peptide libraries to redefine what is possible in your research.

Contact us today to discuss your Bioactive Peptide Discovery project and receive a customized technical proposal from our expert team.

Contact Us Today for a Free Quote!

Frequently Asked Questions (FAQs)

Q: Can I screen against whole cells using your phage-displayed peptide libraries?
A: Yes, we offer "Cell-Panning" services. This is particularly useful for discovering ligands for cell-surface receptors in their native environment without the need for protein purification.
Q: What library diversity do you offer?
A: Our premade peptide libraries typically feature a diversity of 10⁹ to 10¹¹ unique transformants, providing a vast sequence space for identifying high-affinity binders.
Q: Is Repertoire Analysis necessary for every project?
A: While not mandatory, it is highly recommended. Traditional Sanger sequencing only looks at 50–100 clones, which is a tiny fraction of the enriched pool. Repertoire Analysis via NGS examines millions of sequences, significantly increasing the probability of finding the best lead.
Q: How do you handle target-unrelated peptides (TUPs)?
A: We use bioinformatic filters and "subtractive panning" strategies (pre-clearing the library against non-target surfaces) to eliminate peptides that bind to the plastic, the phage itself, or common contaminants.
Q: Can you discover peptides that cross the Blood-Brain Barrier (BBB)?
A: Yes, we utilize in vivo panning and specialized in vitro BBB models to identify bioactive peptides with transcytosis properties.
Q: What is the minimum amount of target protein required?
A: Typically, 1–5 mg of high-purity protein is sufficient for a full discovery campaign. However, this can vary based on the target type and screening strategy.
Q: Do you provide the genetic sequence of the discovered peptides?
A: Absolutely. We provide the full amino acid sequence, the corresponding DNA sequence from the phage clone, and a comprehensive report of the Repertoire Analysis.
Q: Can discovered peptides be used directly for clinical diagnosis?
A: Our services are currently for research use only (RUO). While the leads we discover can be developed into clinical candidates, the discovery phase itself is not intended for direct clinical diagnosis.
Q: What makes Creative Biolabs a leader in the development of peptide ligands?
A: Our dual expertise in molecular biology (phage display) and high-end bioinformatics, combined with two decades of experience across thousands of successful projects, makes us a premier partner in the biotech industry.

Reference

Zhao, Hui, et al. "Phage display-derived peptides and antibodies for bacterial infectious diseases therapy and diagnosis." Molecules 28.6 (2023): 2621. Distributed under Open Access license CC BY 4.0. The image was modified by revising the title. https://doi.org/10.3390/molecules28062621

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.